Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emergency Department Initiation of Airsupra on Asthma Outcomes
NCT07166939Phase 4Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2025
- Primary completion
- Jun 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of salbutamol + budesonide in asthma (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Acute asthma recurrence at 3 months. Started Nov 2025; status: recruiting.
02
Drugs
salbutamol + budesonide
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07166939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07166939.